Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 6/20 | 0.56 |
| ▸ | MTNR1B | P49286 | 5/20 | 0.56 |
| ▸ | EPHX1 | P07099 | 6/20 | 0.50 |
| ▸ | RAB9A | P51151 | 5/20 | 0.50 |
| ▸ | EPHX2 | P34913 | 4/20 | 0.50 |
| ▸ | NPC1 | O15118 | 4/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.50 |
| ▸ | TSHR | P16473 | 2/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | CXCR3 | P49682 | 2/20 | 0.48 |
| ▸ | NQO2 | P16083 | 1/20 | 0.46 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5341399 | 0.79 | MTNR1A (0.62) | MTNR1AMTNR1BRAB9ANPC1SMN1; SMN2 | |
| SCHEMBL5342319 | 0.79 | MTNR1A (0.66) | MTNR1AMTNR1BNQO2 | |
| SCHEMBL5340503 | 0.78 | EPHX2 (0.53) | EPHX1RAB9AEPHX2NPC1SMN1; SMN2 | |
| SCHEMBL5345518 | 0.76 | MTNR1A (0.56) | MTNR1AMTNR1BEPHX1RAB9AEPHX2 | |
| SCHEMBL5340676 | 0.75 | MTNR1A (0.71) | MTNR1AMTNR1BSMN1; SMN2NQO2MEN1 | |
| SCHEMBL5334945 | 0.74 | MTNR1A (0.70) | MTNR1AMTNR1BSMN1; SMN2NQO2MEN1 | |
| SCHEMBL5335200 | 0.74 | MTNR1A (0.70) | MTNR1AMTNR1BSMN1; SMN2NQO2MEN1 | |
| SCHEMBL5337569 | 0.74 | MTNR1A (0.70) | MTNR1AMTNR1BSMN1; SMN2NQO2MEN1 | |
| SCHEMBL5341352 | 0.74 | MTNR1A (0.70) | MTNR1AMTNR1BSMN1; SMN2NQO2MEN1 | |
| SCHEMBL5339601 | 0.74 | MTNR1A (0.58) | MTNR1AMTNR1BNQO2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7183318-B2 | Substituted cyclic compounds, preparation method and pharmaceutical compositions containing them | LES LABORATOIRES SERVIER (FR) | 2007-02-27 | — | — | US | disclosed |
| EP-1077928-B1 | NOVEL SUBSTITUTED CYCLIC COMPOUNDS, PREPARATION METHOD AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | SERVIER LAB (FR) | 2005-12-07 | — | — | EP | disclosed |
| US-20040002490-A1 | Substituted cyclic compounds, preparation method and pharmaceutical compositions containing them | LESIEUR DANIEL (FR) | 2004-01-01 | — | — | US | disclosed |
| US-20040002491-A1 | Substituted cyclic compounds, preparation method and pharmaceutical compositions containing them | LESIEUR DANIEL (FR) | 2004-01-01 | — | — | US | disclosed |
| US-6605632-B1 | Affinity for melatonin receptors | LES LABORATOIRES SERVIER (FR) | 2003-08-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040002491-A1 | Substituted cyclic compounds, preparation method and pharmaceutical compositions containing them | CYP4B1, CYP3A5, MC2R | MTNR1A 388/4885MTNR1B 325/4885EPHX1 929/4885 |
| US-20040002490-A1 | Substituted cyclic compounds, preparation method and pharmaceutical compositions containing them | CYP3A5, CYP4B1, MC2R | MTNR1A 409/4885MTNR1B 340/4885EPHX1 1045/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.